Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.
Poll|Articles|September 5, 2023
POLL: What Topical Treatments Do You Find the Most Efficacious in Acne Vulgaris Management?
Author(s)Dermatology Times Staff
Click here to answer this week's acne poll.
Advertisement
What topical treatments do you find the most efficacious in acne vulgaris management?
Do your patients also follow adherence guidelines with the above medications? Share your experiences with us and any additional acne vulgaris treatment pearls by emailing
For more insights on acne vulgaris management, read our most recent Frontline Forum series, "
Advertisement
Related to this article
Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
Explore trending plant oils in skincare and haircare, plus 2026’s hottest actives like ectoin and hypochlorous acid—balancing glow, barrier repair, and irritation risks.
Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases.
Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Menopause and the Skin: Recognizing Changes Beyond Aging
3
Social Media Mythbusters: Can Face Taping Really Prevent Wrinkles?
4
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
5